Caroline Lamarche

Title: Caroline Lamarche: Innovator in Anti-HLA-A2 Antibodies

Introduction

Caroline Lamarche is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of immunology, particularly in the development of anti-HLA-A2 antibodies. With a total of two patents to her name, her work has the potential to impact therapeutic approaches in various medical applications.

Latest Patents

Lamarche's latest patents include "Anti-HLA-A2 antibodies and methods of using the same" and "Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof." The first patent provides humanized anti-HLA-A2 antibodies that can constitute an antigen binding domain of a chimeric antigen receptor (CAR). This CAR can be expressed in human cells, allowing for specific binding to HLA-A2. The second patent relates to a novel anti-HLA-A2 antibody and a chimeric antigen receptor that includes this antibody. It also discusses immune cells expressing the chimeric receptor and their therapeutic uses, particularly in treating or preventing graft rejection or graft-versus-host disease (GVHD).

Career Highlights

Throughout her career, Caroline Lamarche has worked with esteemed organizations such as the University of British Columbia and CDRD Ventures Inc. Her research and innovations have positioned her as a key figure in the field of antibody development.

Collaborations

Lamarche has collaborated with notable professionals in her field, including Megan Levings and Paul Orban. These collaborations have further enhanced her research and contributions to immunology.

Conclusion

Caroline Lamarche's work in developing anti-HLA-A2 antibodies showcases her innovative spirit and dedication to advancing medical science. Her patents and collaborations reflect her significant impact on the field, paving the way for future advancements in therapeutic applications.